Revealing on April 30: Are You Ready for the Upcoming Election Surprise?
Here is the latest financial fact sheet of GLENMARK PHARMA. For more details, see the GLENMARK PHARMA quarterly results and GLENMARK PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.8 |
No. of shares | m | 282.19 |
1 Week | % | 3.5 |
1 Month | % | 12.9 |
1 Year | % | 108.9 |
52 week H/L | Rs | 1,096.0/514.6 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
GLENMARK PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 712 | 660 | 573 | 691 | 487 | |
Low | Rs | 484 | 168 | 195 | 416 | 349 | |
Sales per share (Unadj.) | Rs | 349.6 | 377.1 | 387.8 | 436.1 | 460.4 | |
Earnings per share (Unadj.) | Rs | 32.8 | 27.5 | 34.4 | 35.2 | 13.4 | |
Diluted earnings per share | Rs | 32.8 | 27.5 | 34.4 | 35.2 | 13.4 | |
Cash flow per share (Unadj.) | Rs | 44.3 | 42.3 | 50.1 | 52.5 | 35.0 | |
Dividends per share (Unadj.) | Rs | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | |
Adj. dividends per share | Rs | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | |
Avg Dividend yield | % | 0.3 | 0.6 | 0.7 | 0.5 | 0.6 | |
Book value per share (Unadj.) | Rs | 198.3 | 214.7 | 249.6 | 321.4 | 335.1 | |
Adj. book value per share | Rs | 198.3 | 214.6 | 249.6 | 321.4 | 335.1 | |
Shares outstanding (eoy) | m | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | |
Price / Sales ratio | x | 1.7 | 1.1 | 1.0 | 1.3 | 0.9 | |
Avg P/E ratio | x | 18.2 | 15.0 | 11.2 | 15.7 | 31.3 | |
P/CF ratio (eoy) | x | 13.5 | 9.8 | 7.7 | 10.5 | 11.9 | |
Price / Book Value ratio | x | 3.0 | 1.9 | 1.5 | 1.7 | 1.2 | |
Dividend payout | % | 6.1 | 9.1 | 7.3 | 7.1 | 18.7 | |
Avg Mkt Cap | Rs m | 168,617 | 116,775 | 108,353 | 156,067 | 117,953 | |
Total wages/salary | Rs m | 20,561 | 22,548 | 23,437 | 24,474 | 27,810 |
GLENMARK PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 98,655 | 106,410 | 109,439 | 123,049 | 129,901 | |
Other income | Rs m | 2,081 | 1,596 | 502 | 1,667 | 3,168 | |
Total revenues | Rs m | 100,736 | 108,006 | 109,941 | 124,716 | 133,069 | |
Gross profit | Rs m | 17,530 | 17,310 | 21,289 | 20,594 | 15,125 | |
Depreciation | Rs m | 3,259 | 4,172 | 4,436 | 4,867 | 6,113 | |
Interest | Rs m | 3,346 | 3,773 | 3,531 | 2,981 | 3,496 | |
Profit before tax | Rs m | 13,006 | 10,961 | 13,825 | 14,412 | 8,685 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 3,756 | 3,201 | 4,124 | 4,476 | 4,911 | |
Profit after tax | Rs m | 9,250 | 7,760 | 9,701 | 9,936 | 3,774 | |
Gross profit margin | % | 17.8 | 16.3 | 19.5 | 16.7 | 11.6 | |
Effective tax rate | % | 28.9 | 29.2 | 29.8 | 31.1 | 56.5 | |
Net profit margin | % | 9.4 | 7.3 | 8.9 | 8.1 | 2.9 |
GLENMARK PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 66,968 | 68,036 | 73,596 | 82,823 | 98,737 | |
Current liabilities | Rs m | 40,211 | 41,260 | 42,010 | 46,894 | 50,455 | |
Net working cap to sales | % | 27.1 | 25.2 | 28.9 | 29.2 | 37.2 | |
Current ratio | x | 1.7 | 1.6 | 1.8 | 1.8 | 2.0 | |
Inventory Days | Days | 5 | 6 | 7 | 6 | 7 | |
Debtors Days | Days | 81 | 83 | 86 | 92 | 115 | |
Net fixed assets | Rs m | 52,090 | 64,255 | 67,093 | 71,148 | 76,920 | |
Share capital | Rs m | 282 | 282 | 282 | 282 | 282 | |
"Free" reserves | Rs m | 55,664 | 60,286 | 70,148 | 90,421 | 94,281 | |
Net worth | Rs m | 55,946 | 60,568 | 70,430 | 90,703 | 94,563 | |
Long term debt | Rs m | 35,738 | 40,430 | 38,888 | 25,717 | 38,521 | |
Total assets | Rs m | 119,058 | 132,291 | 140,689 | 153,972 | 175,658 | |
Interest coverage | x | 4.9 | 3.9 | 4.9 | 5.8 | 3.5 | |
Debt to equity ratio | x | 0.6 | 0.7 | 0.6 | 0.3 | 0.4 | |
Sales to assets ratio | x | 0.8 | 0.8 | 0.8 | 0.8 | 0.7 | |
Return on assets | % | 10.6 | 8.7 | 9.4 | 8.4 | 4.1 | |
Return on equity | % | 16.5 | 12.8 | 13.8 | 11.0 | 4.0 | |
Return on capital | % | 17.8 | 14.6 | 15.9 | 14.9 | 9.2 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 62,998 | 47,737 | 35,753 | 32,142 | 46,464 | |
Fx outflow | Rs m | 22,859 | 18,881 | 12,023 | 13,482 | 12,712 | |
Net fx | Rs m | 40,140 | 28,856 | 23,729 | 18,660 | 33,751 |
GLENMARK PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 13,242 | 13,924 | 11,312 | 11,087 | 6,254 | |
From Investments | Rs m | -6,990 | -7,835 | -6,752 | -3,333 | -5,285 | |
From Financial Activity | Rs m | -7,387 | -4,447 | -4,418 | -5,205 | -775 | |
Net Cashflow | Rs m | -2,971 | 1,740 | 278 | 2,724 | 325 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Glenn Saldanha | COMP SEC: Harish Kuber | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.2 |
Read: GLENMARK PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare GLENMARK PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Indian share markets continued the momentum as the session progressed and ended the higher.